Novo Nordisk A/S
NVOHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Novo Nordisk A/S focuses on Drug Manufacturers - General services and products. Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. With a market capitalization of $222.61B, it sits in mega-cap territory. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Market Cap
$222.61B
Beta
0.36
P/E (TTM)
12.36
P/E (Fwd)
14.89
EPS (TTM)
$4.07
EPS (Fwd)
$3.38
ROE
71.4%
ROA
19.3%
Cash
$21.63B
Total Debt
$146.38B
Free CF
-$12.04B
52W Change
-21.8%
Annual Financials
Cash vs Debt
On the balance sheet, NVO has $21.63B in cash with $146.38B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$12.04B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 71.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 19.2% further supports the picture of efficient asset utilization. Revenue has grown from $176.95B (2022) to $309.06B (2025), reflecting a 75% increase over the period.
With a beta below 0.7, Novo Nordisk A/S typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Novo Nordisk A/S carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing NVO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.